Human Longevity, Inc. and Discovery Ltd to Offer Whole Exome, Whole Genome and Cancer Genome Sequencing to Discovery Insurance Clients in South Africa and the United Kingdom
HLI Introduces a Whole Exome Sequencing Product for $250 USD
(SAN DIEGO, CA and SANDTON, SOUTH AFRICA)—September 22, 2015—Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, and Discovery Ltd, a pioneering insurer dedicated to making people healthier, announced today that the two companies have entered into a multi-year agreement to offer whole exome, whole genome and cancer genome sequencing to Discovery’s clients in South Africa and the United Kingdom.